How Will These Marijuana Stocks Perform In The Short Term?

How Will These Marijuana Stocks Perform In The Short Term?




How Will These Marijuana Stocks Perform In The Short Term? | Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™





















Published at Tue, 29 Sep 2020 17:26:09 +0000

3 Canadian Licensed Producers Looking South Of The Border To Drive Future Growth

3 Canadian Licensed Producers Looking South Of The Border To Drive Future Growth

2020 was supposed to be a breakout year for the Canadian cannabis industry after Health Canada approved regulations in late 2019 that would allow companies to sell cannabis derivative products (i.e. edibles, vape pens, concentrates, topicals, and more).

So far this year, the most important growth driver for the cannabis industry has been the US market. Despite the rollout of cannabis derivative products in Canada, the market continues to be under pressure, and this is a trend that we are following.

One of the most important trends that we have noticed with from Canadian cannabis producers is related to the opportunity in the US and believe that this could be signaling the end of the Canadian cannabis trade. Today, we want to highlight 3 leading Canadian cannabis producers that have become focused on the US market and believe that this is the start of a much more significant trend.

Canopy Growth: Positioned to Capitalize on the US Market

Since 2014, Canopy Growth Corporation (WEED.TO) (CGC) has been considered the leading Canadian cannabis company. We have been following the company since it commenced trading in 2014 and have been impressed with how the management team has been able to turn it into the industry leader that it is today.

With more than $2 billion of cash on the balance sheet, Canopy Growth can afford to make mistakes and still be considered an industry leader. The company has made its fair share of mistakes that resulted in the firing of the Founder and CEO Bruce Linton in 2019.

Prior to the firing of Bruce, Canopy Growth was already focused on the US cannabis market through a merger agreement with Acreage Holdings, a multi-state US cannabis retailer. When the agreement was reported, the market responded very favorably to the deal and the shares surged higher.

Following the signing of the agreement, Canopy Growth became highly focused on the hemp market in the US and formed a relationship with Martha Stewart. The relationship with Martha Stewart is the second celebrity that Canopy Growth has signed a deal with (the first one was Snoop Dogg) and we are favorable on the brand awareness that was created through it.

Canopy Growth is quietly positioning itself to capitalize on the US market once cannabis is no longer illegal at the federal level. In regard to Acreage Holdings, the companies recently amended the agreement and Canopy Growth will need to make an up-front payment of more than $37.5 million to Acreage shareholders. Under the original agreement, Canopy was supposed to pay more than $300 million to Acreage shareholders and we find the change to be substantial.

Over the next year, we expect to see Canopy Growth take additional steps to position itself to capitalize on the US cannabis market. The new management team is comprised of executives that have a proven track record of success in a variety of industries and we will monitor how they are able to drive the story forward.

Aurora Cannabis Bets Big on the US CBD Market

Aurora Cannabis Inc. (ACB.TO) (ACB) is another Canadian cannabis producer that has recently become focused on the US market. When compared to Canopy Growth, the company is taking a much different approach to the US market and recently announced the acquisition of Reliva, a CBD brand.

Aurora Cannabis was once considered to be a darling on Wall Street. Now, the company cannot raise equity capital and is fighting to survive. In order to stay listed on the NYSE, Aurora Cannabis was forced to conduct a reverse stock split and this is a trend that we have been closely following.

Following the reverse split, Aurora has continued to be under pressure, and we continue to remain cautiously optimistic with the opportunity. We believe that there is a lot of operation risk associated with Aurora Cannabis and the management team will need to execute in order to stay alive.

Last month, rumors about a potential merger between Aurora Cannabis and another leading Canadian cannabis producer surfaced and the market initially responded favorably to it. Although we would not be surprised if Aurora merged with a similar sized business or was acquired by a larger cannabis business, we continue to remain cautious with long-term opportunity.

During the last quarter, several leading broker-dealers that cover the cannabis industry have gone negative on Aurora Cannabis and have been lowering price targets on the stock. We believe that the company is betting big on the US CBD market to turn the story around and are not too confident in the strategy.

HEXO: A Cannabis Beverage Execution Story

In 2018, HEXO Corporation (HEXO.TO) (HEXO) made headlines when it reported to have formed a strategic relationship with Molson Coors (TAP.CN). Although it took almost two years for the relationship to report something substantial, the companies formed Truss Beverage Co. and recently introduced 5 cannabis beverage brands to the Canadian cannabis market.

Through the relationship with Molson, HEXO plans to capitalize on the US CBD industry and plans to launch cannabis beverages in strategic markets. Once cannabis is no longer illegal in the US, we expect the relationship to launch THC drinks in the US and are bullish on the amount of value that can be generated through it.

Although HEXO’s initial focus on the US market is small, we believe that something is better than nothing and will monitor how the story evolves from here. Molson provides HEXO with substantial distribution in the US and expect this to play an important role in the success of the relationship.

During the last year, HEXO has been under substantial pressure and we believe that the relationship with Coors could prove to be the catalyst that the Canadian cannabis producer needed. We believe that the relationship with Molson Coors is a key pillar of the HEXO opportunity and will monitor how it benefits both businesses over the long-term.

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Tue, 29 Sep 2020 10:42:45 +0000

Hawaii Governor Signs Law Allowing the Sale of Cannabis Edibles

Hawaii Governor Signs Law Allowing the Sale of Cannabis Edibles

Solace Enterprises, LLLP and its public-facing business Aether Gardens have settled a federal lawsuit with Case Mandel and his company Trinidad Consulting, LLC, doing business as Cannadips, according to records from the U.S. District Court for the District of Nevada.

Records from the U.S. District Court for Nevada said the parties reached a settlement in late July and that the court dismissed the case “without prejudice.” This means a plaintiff can sue again, according to Nolo’s Plain-English Law Dictionary

U.S. District Judge Jennifer A. Dorsey’s order to dismiss the case, dated Aug. 4, states “each side [is] to bear its own fees and costs.”

***

Originally published July 8

A federal court case involving plaintiffs Solace Enterprises LLLP, Aether Gardens and Telloni Holdings Limited and defendants Trinidad Consulting and Cannadips has been stayed following mediation on June 18, according to federal court records. The parties are working together on a settlement.

The plaintiffs alleged the defendants owed them $1.2 million in loans, according to the original complaint, while the defense claims Trinidad and Cannadips expected royalties.

Solace Enterprises LLLP does business as Aether Gardens and in some court documents is referred to as Solace Holdings LLLP. The company holds two active production licenses and two active cultivation licenses in North Las Vegas, Nev., to service the adult-use and medical cannabis markets, according to Nevada’s Cannabis Compliance Board. A Solace Enterprises LLLP hemp processing license has expired, according to Cannabiz Media.

Founded in 2018, Aether Gardens aims to become “the leader in brand development, white label manufacturing & research providing both medical & recreational cannabis consumers with the best experiences,” according to its website, where the company describes plans to develop a 90,000-square-foot “state-of-the-art manufacturing facility” for cultivation, extraction and production.

Cannadips possesses an active “Manufacturer Annual Infusions” license in Arcata, Calif., according to Cannabiz Media. Two Cannadips “Manufacturer Temporary Infusions” have expired, along with all other licenses of the same type in the state, according to the site. A Trinidad Consulting LLC “Manufacturer Temporary Infusions” license in Humboldt County has also expired, per the website.

Established in 2016, Cannadips manufactures a cannabidiol (CBD) dip product and is “shifting the paradigm of tobacco by providing a great-tasting, nicotine-free alternative tobacco product,” according to its website. The product is formulated with “American hemp” and “rooted in Humboldt.”

Attorneys for the plaintiffs and defense declined, through public relations representatives, Cannabis Business Times’ and Hemp Grower’s requests for comment about the mediation or settlement.

Published at Tue, 29 Sep 2020 16:13:00 +0000

Lexaria Bioscience Receives Conditional Ethics Board Approval for Pilot Human Study Using DehydraTECHTM Technology in Delivering Antiviral Drugs

Lexaria Bioscience Receives Conditional Ethics Board Approval for Pilot Human Study Using DehydraTECHTM Technology in Delivering Antiviral Drugs

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today provides an update on a previously announced antiviral research initiative and introduces a new research project with potential COVID-19 applications.

On March 19 2020, Lexaria announced that it planned to conduct a pilot human pharmacokinetic exploratory study in healthy volunteers of antiviral drugs that have previously been studied against other coronavirus strains, comparing Lexaria’s  DehydraTECHTM formulations to controls without Lexaria’s technology.

The ethics board approval required as a first step in this pilot study has now been received, conditional on further government regulatory approval also being granted. Lexaria will now begin the process of pursuing the necessary steps to file for approval from federal regulators.

In parallel with this, Lexaria is also announcing the launch of a separate rodent antiviral study to evaluate pharmacokinetic benefits from the use of DehydraTECH in the delivery of representative drugs from two classes of antiviral drugs heavily under investigation against COVID-19 today. The drugs to be used have already been processed with DehydraTECH and sent to the testing facility. Dosing of the rodents has already begun and study results are expected in December 2020.

“We are excited at this progress towards our pilot human study using our patented DehydraTECH platform in the delivery of antiviral drugs, and are continuing the process towards regulatory approval so we can advance this important study,” said Chris Bunka, CEO of Lexaria. “Additionally, we are pleased to have started an animal study using DehydraTECH on certain potential COVID-19 drugs under investigation. Not only will this study help to determine whether DehydraTECH is capable of delivering higher proportionate doses of the antiviral drugs than generic versions of the drugs, but the outcomes should also be beneficial in gaining regulatory approval for the planned human study.”

As background, many antiviral drugs are fat soluble and known to present significant bioavailability challenges in successfully reaching the human bloodstream in therapeutic quantities when administered in oral form. Lexaria’s expertise in the enhanced oral delivery of fat-soluble drugs could offer significant benefits to antiviral drug administration that potentially could remove the need for costly and uncomfortable injected treatments frequently used today.

Additional research may include expanded pharmacokinetic and pharmacodynamic screening, including studies in appropriate coronavirus animal models with the antiviral drugs Lexaria is currently investigating and/or others from their classes for efficacy evaluation. If Lexaria’s technology is proven to increase delivery effectiveness of antiviral drugs, the Company will make its technology available to researchers throughout the world looking to maximize the effectiveness of their own drug investigations.
Enhancement of delivery properties of antiviral drugs is consistent with Lexaria’s strategy as a drug delivery platform innovator for multiple applications. The Company believes DehydraTECH may prove useful in the fight against COVID-19 and other viruses that are expected to be investigated in the future.  Chris Bunka, CEO, is responsible for the accuracy of this news. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

About Lexaria
Lexaria Bioscience Corp.’s (OTCQX: LXRP, CSE: LXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 – 2 hours to 10 – 20 minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, please visit       www.lexariabioscience.com.

INVESTOR CONTACT:
ir@lexariabioscience.com
Phone: 866-221-3341

FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company’s ability to carry out the antiviral research initiatives, receive regulatory approvals or experience positive effects from any antiviral research or study.. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements.  As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, and other factors which may be identified from time to time in the Company’s public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing any active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA).  Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Lexaria Bioscience Corp.
#100-740 McCurdy Road
Kelowna, BC V1X 2P7.
www.lexariabioscience.com

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Tue, 29 Sep 2020 11:08:54 +0000

Namaste Technologies Provides Corporate Update

Namaste Technologies Provides Corporate Update

Namaste Technologies Inc. (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF), a leading online platform for cannabis products, accessories, and responsible education, is pleased to provide a corporate update with regards to a change in management and the settlement of an outstanding claim to the benefit of Company shareholders.

Namaste Technologies Inc. (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) (CNW Group/Namaste Technologies Inc.)

Namaste to Appoint New Interim Chief Financial Officer

The Company is pleased to announce the appointment of Slava Klems , CPA, CA, as interim chief financial officer as of October 31, 2020 . Ms. Klems succeeds Annie Holmes who is leaving Namaste to pursue other opportunities, concluding her role as chief financial officer on October 30, 2020 .

“I would like to welcome Ms. Klems to the position of interim chief financial officer for Namaste,” said Meni Morim , CEO of Namaste Technologies. “She has an impressive background in corporate finance with experience in technology and platform integration and has shown an incredible business acumen since joining the Company. I look forward to working with Ms. Klems as we seek to drive Namaste forward. Additionally, I would like to thank Ms. Holmes for her work at Namaste and her assistance with the seamless transition to Ms Klems over the next few weeks.”

Ms. Klems is an accomplished finance executive with over 10 years experience in senior finance management positions at AIMIA Inc. (Aeroplan) and Dominion Citrus Income Fund, plus experience across diverse industries including retail, distribution, manufacturing, pharmaceutical and automotive sectors. She joined Namaste in July 2020 and has proven herself as a driven and hardworking professional with a proven record in change management, process optimization and improved operational efficiencies. Ms. Klems has also successfully completed multiple ERP software implementation projects, including PeopleSoft and Workday to integrate Operations and Finance functions driving sustainable operational effectiveness. Ms. Klems holds a Master of Science and a Bachelor of Business Administration from York University and earned her Chartered Accountant designation with KPMG.

Trademark Dispute Settlement

Namaste today announced that it has reached a settlement in connection with a trademark dispute involving the use of the trademarks and corresponding registrations of trademarks for “Namaste”, “NamasteVapes”, “Namaste Technologies”, “NamasteMD” and “NamasteCafe” (collectively, the “Trademarks”). Under the terms of the settlement, Namaste will receive a settlement payment in three tranches over the next 12 months from one of the defendants for an aggregate amount of $250,000 (the ” Settlement Fee “). In addition, Namaste has agreed to assign the Trademarks to the same defendant, in exchange for a limited licence for the continued use by Namaste of the Trademarks over the next 12 months in Canada , and the transfer of the domain namastevapes.ca following payment of the final tranche of the Settlement Fee.

The litigation initiated by Namaste in connection with the trademark dispute is expected to be dismissed with the consent of all parties in the coming days. Meni Morim , CEO of the Company, commented, “We are pleased to put this matter behind us and continue writing our own history with a clean slate. Our focus continues to be on the development of our own in-house brands in the various lines of business we operate in such as CannMart and VendorLink. We are also very excited about the re-imagining of our corporate identity, creating a holistic brand positioning across all our assets. We look forward to sharing this with our shareholders, customers and partners in due course.”

About Namaste Technologies Inc.
Headquartered in Toronto, ON , Namaste Technologies is a leading online platform for cannabis products, accessories, and responsible education. The Company’s ‘everything cannabis store’, CannMart.com, provides medical customers with a diverse selection of hand-picked products from a multitude of federally-licensed cultivators, all on one convenient site. The Company also distributes licensed and in-house branded cannabis and cannabis derived products to recreational consumers in Canada through a number of provincial government control boards and retailing bodies and online in Saskatchewan . Namaste’s global technology and continuous innovation address local needs in a burgeoning cannabis industry requiring smart solutions.

Information on the Company and its many products can be accessed through the links below:

NamasteTechnologies.com
NamasteMD.com
Cannmart.com

FORWARD-LOOKING INFORMATION – This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as “may”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, and are not limited to, statements regarding Namaste’s expectations regarding the dismissal of the action described herein and the payments to be made by one of the defendants in connection with the settlement agreement. The forward-looking information contained herein is made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made, including the Company’s expectations relating to the dismissal of the action in the short term with the consent of all parties to such action and the ability of the defendant to make all payments in accordance with the settlement agreement and the full settlement of the said action. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release. Such factors include, without limitation: risks relating to the failure of certain parties to the action consenting to its settlement as contemplated herein and the defendant’s ability to make the payments under the settlement agreement in accordance therewith, . Additional risk factors can also be found in the Company’s current MD&A and annual information form, both of which have been filed under the Company’s SEDAR profile at www.sedar.com . Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Cision

View original content to download multimedia: http://www.prnewswire.com/news-releases/namaste-technologies-provides-corporate-update-301138708.html

SOURCE Namaste Technologies Inc.

Published at Mon, 28 Sep 2020 12:04:00 +0000

Aurora Cannabis and Nelson Peltz Part Ways……… Thanks For Nothing.

Aurora Cannabis and Nelson Peltz Part Ways……… Thanks For Nothing.

One of the few remaining aspects of the Aurora Cannabis (ACB.TO) (ACB) story is no more…

Nelson Peltz has resigned as a senior advisor to the Canadian cannabis producer and we are not surprised by the development. Through 280 Park ACI Holdings, Peltz was involved with Aurora Cannabis and his involvement was an attractive aspect of the story.

When Nelson Peltz joined Aurora Cannabis, we were surprised by his selection. When compared to Canopy Growth Corporation (WEED.TO) (CGC), Aurora Cannabis represented a less capitalized growth opportunity that had a much less attractive capital structure.

Following the completion of a 12-for-1 reverse split, Aurora Cannabis improved the balance sheet by reducing the number of shares outstanding. This transaction did not create any value for Aurora Cannabis and we were surprised to see the shares rally after the development.

We believe that Aurora Cannabis is a fundamentally different business from what it was when Nelson Peltz joined. When he got involved, the company was focused on the Canadian and the international cannabis opportunity. Now, Aurora Cannabis seems to be laser focused on the US cannabidiol (CBD) market and this is a vertical that we are not bullish on.

The US CBD industry is fragmented, and we are cautious with the leverage that Aurora Cannabis has to it. We believe that the name of the game for Aurora Cannabis is execution and the market seems to be fed up with the opportunity. The recent trend has been to the downside and we remain cautiously optimistic with the Canadian cannabis producer.

During the last month, several leading broker-dealers have lowered estimates and price targets on Aurora Cannabis and Peltz’s resignation does not make the situation any better. We believe that the next six months are crucial for the organization and would expect to see the company file for bankruptcy if it is not able to quickly get its act together.

Share

Share - Facebook


Share - Twitter

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Published at Mon, 28 Sep 2020 14:43:48 +0000

Vermont Lawmakers Send Legislation to Regulate Cannabis Sales to Governor, Illinois Gives Dispensary Applicants Another Shot at Licensing Lottery: Week in Review

Vermont Lawmakers Send Legislation to Regulate Cannabis Sales to Governor, Illinois Gives Dispensary Applicants Another Shot at Licensing Lottery: Week in Review

[PRESS RELEASE] Tropizen announced on Sept. 1 the completion of its first commercial cannabis harvest grown in its recently added 10,000 square foot outdoor cultivation facilities. The new harvest, destined for both flower sales and the manufacture of infused medicinal products, arrives as patient demand for cannabis flower in Puerto Rico continues to surpass available market supply.

“This harvest represents an important milestone for our company as we continue to expand to meet patient demand for high-quality flower,” said Tropizen co-founder Marni Meistrell. “We are growing cannabis near the base of El Yunque tropical rainforest, following cultivation best practices as we conduct research and test new strains that thrive in this location.”

An additional 7,000 square feet of outdoor cultivation will be added before the end of the year, according to Meistrell. Tropizen recently expanded its cannabis flower production to 400% of original capacity, at an investment of over $1 million. The expansion project included the construction of the new outdoor cultivation space.

READ MORE: Tropizen Finds Success in Puerto Rico’s Cannabis Market 

The new harvest is comprised of five of the company’s best performing strains. Tropizen rotates 50 primary strains with 5 secondary strains, including Brian Berry Cough, Ogiesel and Agent Orange, all exclusive to Tropizen in Puerto Rico. One of the company’s priorities going forward is the cropping of rare tropical cultivars as part of its ongoing research and development process.

Meistrell said the company is working on the introduction of a new packaging and grading system for its cannabis flower, incorporating a new pre-packaged midgrade flower product that will be more accessible to patients in terms of price, while offering the same effectiveness as the premium flower.

Tropizen was the first cannabis cultivator in the island to offer individually pre-packaged flower to dispensaries instead of bulk cannabis packaging. The former facilitates higher sales volumes for dispensaries. Moreover, patients get a fresher product, as the packaging protects the delicate cannabis flower from exposure to degrading environmental conditions, including oxygen and moisture. Presently, prepackaged flower comprises approximately 20% of the company’s sales to dispensaries.

With lab-tested cannabinoid concentrations of over 20% (and as high as 30%), Tropizen offers product consistency, exceptional plant genetics and attention to detail, according to Novacann Labs Director of Operations Christian Burgos. “Normally we see that quality suffers when production volume increases, however, this has not been our experience with Tropizen. The results from their harvest evidence strict compliance and consistent quality control,” explained Burgos.

As part of its cultivation protocol, Tropizen uses live soil with beneficial insects in its outdoors cultivation facilities, as well as organic processes. An outside entomologist serves as technical advisor and conducts weekly inspections of the plants. Moreover, chemical pesticides are not used.

Meistrell noted that cannabis flower has been in short supply in Puerto Rico this summer. “Dispensaries are consistently running out of product even though our volume has increased. We seem to be approaching a worrisome scenario where patients have a harder time acquiring their medicine, driving prices up.” The growth in patient numbers may be a contributing factor but official figures have not been published so far this year.

Published at Sat, 26 Sep 2020 12:30:00 +0000

New Bill in Congress Would Allow Cannabis Businesses to Access Federal Disaster Relief Programs

New Bill in Congress Would Allow Cannabis Businesses to Access Federal Disaster Relief Programs

In early September, a sudden frost stretched across portions of Colorado and neighboring states, causing alarm for hemp farmers just weeks out from harvest. In some cases, highs dropped to around the freezing point; lows hovered in the 20s.

In ideal conditions, hemp is harvest before any frost hits the farm. The crop tends to be somewhat “frost-tolerant,” as the University of Vermont’s 2018 Hemp Cold Tolerance Trial lays out, but farmers should certainly watch out for related changes in moisture levels and even more unusual effects, like branches snapping under the weight of attendant snow. 

We spoke with Derek Thomas, vice president of business development at Veritas Farms, a Pueblo, Colo.-based hemp operation, to get a sense of how his company monitors the twists and turns of weather patterns in late summer and early fall. In Pueblo, Veritas got away from the early frost with its 140 acres of hemp fairly unscathed.

But this wasn’t the first time a sudden temperature drop has affected the farm, and lessons abound for all farmers eager to adjust their pre-harvest protocol.

Eric Sandy: What was early September like for Veritas Farms? And what sort of weather monitoring system is in place for the company?

Derek Thomas: It’s such an important topic, especially for a fully vertically integrated brand, because ultimately our crop is our commodity. It’s our lifeblood. So, we’re very cautious. We’re very considerate and we’re always monitoring. We have a number of SOPs implemented at the farm, which help us mitigate any severe weather concerns, both from a monitoring perspective and an action item standpoint. So, we knew that [this early frost] was coming, unfortunately, and we prepped the best we could and we took action immediately after.

And the damage was pretty negligible this year. We really kind of came out of it unscathed. Where we are, the temperature of the day before was a nice 80 degrees, and the snow really melted before the end of the day. So, the ground stayed nice and warm, and the roots of the plants stayed pretty warm. We were pretty fortunate, at least in our neck of the woods, that no real damage was done.

ES: What are some of the red flags or warning signs that farmers might want to watch out for when we’re talking about those colder temperatures and snowy situations?

DT: You know, it’s definitely going to depend where you’re at in your growing cycle. When we’re coming into late summer and early fall, that’s obviously when a lot of plants are pretty far along in the process. You’re really monitoring humidity levels and ground temperature, but anything that trends toward freezing is when we start to monitor and engage— anything in the low 50s, in the 40s, that’s when we’re starting to pay attention. The closer we get to freezing, that’s where more of our thresholds are triggered in terms of additional monitoring or even action items. So, it’s really the temperature that we’re monitoring the hardest.

Actually, two years ago, we had another early frost and it was quite a bit more severe. It triggered a bit of an early harvest and it also inspired us over the past year to play around with some new genetics. And that’s another reason why we were really fortunate this year that that frost has affected us even less. The plants on our farm are a little bit squattier. They’re not the really tall kind of plants that you see in some other areas of the country. They’re really squatty. And they’re really hearty and sturdy. We didn’t really have to worry about branch breakage from the weight of the snow. And the ground didn’t necessarily freeze, so that was really good for us.

In fact, from what we’ve seen so far this year, the frost actually might’ve benefited us a little bit. It causes a swelling in the moisture inside of the plant. And, really, what we’re noticing is that our buds are a little bit swollen in a good way. We’re not forecasting any type of negative impact from that snow.

ES: Hemp crops are, of course, in many situations, outdoors and fairly vulnerable to the elements. Are there any physical defenses that might be helpful to think about—whether that’s a literal covering or anything like that?

DT: I know that we haven’t done [that] yet because we’re talking about acres and acres and acres. I think that it could help a smaller grow. That might be more feasible. I’m not sure that the infrastructure exists yet for some type of large-scale covering. Although I do know that’s kind of a standard practice in some other agricultural commodities.

One of the main things that we look to do is monitor the water supply of the plants. The less water that is in the ground around the roots before frost, the less chance you have of freezing those roots, which is obviously something that we definitely want to avoid. Depending on the length and severity of the frost, this is really going to depend on some of the actions that you put in. The first one that we always go to is monitoring the moisture level in the ground, because the last thing you want is for the ground to freeze.

Published at Fri, 25 Sep 2020 15:09:00 +0000

Petition Pushes for National Medical Cannabis Insurance For Canadians

Petition Pushes for National Medical Cannabis Insurance For Canadians

A new healthcare technology company, Cannalogue, is launching a petition in their native land of Canada to get the Ministries of Health on board with providing national healthcare coverage for medical cannabis. 

The petition, entitled United for Access, was started because of the financial burden the COVID-19 pandemic has had on many Canadians, especially those who are already marginalized or disadvantaged, according to a press release the company sent out. Cannalogue believes Canadian citizens should have access to cannabis health care as well as general healthcare. 

“More than 50 percent of Canadians are not able to afford treatment with medical cannabis including CBD for conditions such as chronic pain,” their website states. “Due to COVID-19, Cannalogue anticipates these figures will worsen given the economic challenges facing Canadians. The doctors at Cannalogue believe this will cause a spike in opioid prescriptions, resulting in more opioid related addictions and deaths. When safer medications like medical cannabis and CBD are available, all Canadians should have fair and equal access as part of universal healthcare. Sign the United Program for National Medical Cannabis Coverage petition today and join us as we fight to remove the barriers that prevent access to safer medicines for Canadians.”

Read More

Published at Fri, 25 Sep 2020 15:01:41 +0000